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ers of overuse across HRRs in the US. Structural variations imply that the causes of 
widespread overuse can be identified and potentially controlled.
PRM30
Should deciSion MakeRS eMbRace non-conStant diScounting?
Paulden M., McCabe C.
University of Alberta, Edmonton, AB, Canada
Objectives: Much recent debate has focused on the merits of differential discount-
ing of costs and health effects. Yet relatively little attention has been paid to the 
merits of using discount rates that are time-dependent (i.e. non-constant). Recent 
theory shows that appropriate discount rates depend upon the real rate of borrow-
ing. Since this is determined by the bond market, and since real yields differ on 
bonds of different maturity, this implies that discount rates ought to be non-con-
stant. Recent research has also demonstrated that conventional objections to non-
constant discounting, such as the risk of time-inconsistency, may no longer hold. 
Our objective is to shed light on this under-researched topic and to ignite a debate 
about the merits of non-constant discounting. MethOds: We review the theoreti-
cal and empirical literature around the use of non-constant discounting, consider 
whether non-constant discounting is appropriate for social decision making, and 
(if so) propose how decision makers can incorporate non-constant discounting in 
a way that is time-consistent and which accounts for intergenerational equity and 
other social value considerations. We also consider, and propose solutions to, tech-
nical hurdles associated with adopting non-constant discounting. Results: The 
conventional approach to discounting (using a constant rate) is appropriate only 
in special cases where specific assumptions are adopted. In general, non-constant 
discounting is preferable. Recent work has overcome both the theoretical and tech-
nical hurdles to the adoption of non-constant discounting cOnclusiOns: Decision 
makers should reconsider their existing discounting methodology to ensure that it 
is compatible with their perspective on social choice, any budget constraints faced, 
and other considerations. Where non-constant discounting is found to be appropri-
ate, it should be embraced by decision makers.
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exPlicative Model of the health exPendituRe foR contRibutive 
health SubSySteM PoPulation in coloMbia
Romero M.1, Marrugo R.1, Acero G.1, Quinche G.2, Grosso G.3, Lee J.1, Moreno Y.4, Lee J.2, 
Reinales J.2, Vivas D.5
1Salutia´s Foundation- Research center in economy, management and health technologies., Bogota, 
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group, Bogotá, Colombia, 5Universidad Politécnica de Valencia, Valencia, Spain
Objectives: estimate the per capita income and the global attention expenditure 
for a person that is part of the contributive health subsystem, through an econo-
metric model, using a clinical diagnosis group of patients, which permit the suf-
ficiency resources evaluation. MethOds: Using an econometric model developed 
from information detailed health expenditure of 9.6 million members attended and 
unattended in four different insurers, he sought to build an explanation of expendi-
ture information 2013, using three categories of variables: sociodemographic (age, 
sex), chronic (ten groups) and risk factors. To estimate the function a multiple regres-
sion was used to identify statistically significant variables that explain spending 
the best model, low goodness of fit and reporting criteria. Reliability tests on indi-
vidual basis and robustness tests for each variable and the model generally applied. 
Furthermore, deviations between different insurers were identified. Results: The 
final linear function includes 18 different variables, all significant at 10%, with an R2 
of 7.03%. The estimation shows that men are spending on average lower than that of 
women. The differences in betas by age groups were not significant, but different in 
the groups with chronic diseases and comorbidity. Can be estimated average costs 
for patients with chronic diseases. When testing model fit on the same database, 
there is a goodness of fit of 99%, where health spending in real per capita was $ 
447,375 versus estimated by the model equals $ 447,370. cOnclusiOns: estimating 
a model that includes variables associated with the disease gives higher accuracy 
than when only demographic variables are used and allow a more equitable dis-
tribution of risk-based resources and could be a better alternative in defining the 
insurance premium for a country like Colombia.
PRM32
SuggeStion of new MethodS to calculate confidence inteRval foR 
incReMental coSt-effectiveneSS Ratio which Solve the iSSueS with 
conventional Method
Aranishi T., Ikeda S.
International University of Health and Welfare, Ohtawara City, Japan
Objectives: To review the issues in calculating confidence intervals (CIs) of the 
incremental cost-effectiveness ratio (ICER) with conventional methods and to pro-
pose new methods defining more appropriate ranges to evaluate the uncertainty 
of cost-effectiveness analysis. Conventional methods to calculate CIs first obtain 
the cost-effectiveness plane through Monte Carlo simulation. Next, 95% of the 
distribution is surrounded with two lines that pass through the origin, and the 
slopes of these two lines will be assumed to be the upper and lower CIs. In some 
situations, the methods yield CIs that are separated as -∞to upper limit and lower 
limit to ∞. On the contrary, CIs are not defined if any two lines surround 95% of the 
distribution. MethOds: We propose two modifications on methods for construct-
ing ICER CIs. One is to surround 95% of the distribution with two segments from 
the origin (method 1). Another is to report just the upper or lower limit defined in 
the first quadrant if the CIs are not appropriately defined (method 2). We evalu-
ated the performance of the existing and proposed methods (method 1, method 
2 and a combination of both) using simulations that calculate ICER CIs on three 
situations. Results: Our simulations revealed that the results from the proposed 
methods are similar to those from the conventional ones under the situation that 
the latter can yield the fair CIs (situation 1). However, under the situations that con-
ventional methods cannot appropriately define the CIs (situation 2; CIs separated, 
Objectives: Previous reviews of cost-effectiveness analyses (CEAs) of varicella 
vaccination have concluded that dynamic transmission models should be used 
to properly account for indirect effects of vaccination. This study reviews CEAs of 
varicella vaccination that used a dynamic model to identify parameters with the 
greatest impact on the CEA results. MethOds: A targeted search of MEDLINE was 
conducted for childhood varicella vaccination CEAs that used a dynamic model. We 
assessed the structural assumptions and input parameters that had the greatest 
impact on the cost-effectiveness results and summarized the ranges of input val-
ues and primary data source. Results: Fourteen varicella vaccination CEAs using 
a dynamic transmission model were identified. The results of these studies were 
most sensitive to 2 structural assumptions: 1) inclusion of zoster and 2) inclusion 
of indirect costs. For example, whether or not zoster was included changed results 
from “cost saving” to exceeding country-specific thresholds for cost-effectiveness. 
These results depended on the assumed magnitude of the impact of varicella vac-
cination on zoster cases and the time horizon for the CEA. Three input parameter 
values also substantially impacted the results: 1) vaccine-related costs depending 
on if 1 or 2 doses of vaccine were evaluated, 2) estimates of productivity loss per case 
of varicella (0.27 to 8.8 days for caregivers of children, 2.6 to 26.1 days for adults) and 
3) estimates of QALY loss per case of natural varicella (0.0027 to 0.004 [uncompli-
cated case], 0.0038 to 0.017 [complicated case]), per case of breakthrough varicella 
(20% to 50% of natural case value), and per case of zoster (0.01 to 0.12 [younger/
less severe case], 0.201 to 0.52 [older/more severe case]). cOnclusiOns: Future 
research should be prioritized for epidemic and economic parameters for which 
there is large uncertainty and that impact the results and, consequently, decisions 
about varicella vaccination programs.
PRM28
iMPlicationS of the inteR-RelatedneSS of the PRoPoRtional and 
abSolute Qaly ShoRtfall MeaSuReMentS foR diSeaSe buRden
Kusel J., Beale R.C., Maruszczak M.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: Health technology appraisal bodies such as NICE in the UK have 
shown interest in using the absolute and proportional quality adjusted life year 
(QALY) shortfall to represent aspects of disease burden. NICE originally proposed in 
their value based assessment consultation paper that additive cost-effectiveness 
threshold weightings could be applied according to both the absolute and pro-
portional QALY shortfalls. This analysis sought to understand the relationship 
between the absolute and proportional shortfall and therefore whether the pro-
posal by NICE was justified. MethOds: The conditions selected were identified 
from NICE single technology appraisals published between July 2011 and December 
2014. The age that treatment commenced was taken from manufacturer models 
and combined with the gender-dependent average life expectancy and age- and 
gender-dependent utilities in the UK to calculate the discounted QALYs accrued 
by a healthy person (X). Discounted QALYs accrued by current treatment were 
extracted from manufacturer submissions (Y). Consequently, absolute (X-Y) and 
proportional (absolute/X) QALY shortfalls were calculated for each condition. The 
data were analysed using linear OLS regression, with the absolute shortfall being 
the dependent variable. Appraisals were excluded if the manufacturer submission 
was missing or if the time horizon was not lifetime. Results: The absolute and 
proportional QALY shortfalls were calculated for 43 conditions. The regression 
line had equation y = 13.0x + 0.005 and the r-squared value was 0.84, indicating 
that there is a strong positive correlation between absolute and proportional QALY 
shortfall. This is not surprising given that the variables are mathematically cou-
pled. cOnclusiOns: Absolute and proportional QALY shortfall are not independ-
ent variables, but are mathematically related, and therefore bodies such as NICE 
should avoid assigning additive weights to these measures. If additive weights 
were assigned, conditions where the QALY does not fully capture the benefits of 
new technologies would be particularly disadvantaged.
PRM29
exPloRing Potential dRiveRS of the SySteMatic oveRuSe of 
healthcaRe in the united StateS uSing the JohnS hoPkinS oveRuSe 
index (Jhoi)
Bridges J.F.1, Zhou M.1, Segal J.2
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins 
University, Baltimore, MD, USA
Objectives: The Johns Hopkins Overuse Index (JHOI) was designed as a composite 
measure of systematic overuse that was operational in claims data. Unlike measures 
of geographic variation, it uses detailed algorithms to identify instances where the 
procedure is used in patients that are unlikely to benefit. Using multi-level modeling 
techniques to measure overuse across 306 Hospital Referral Regions (HRRs), the 
JHOI has been shown to be highly predictive of higher costs and worse outcomes 
in an HRR. The purpose of this study was to explore possible drivers of overuse by 
comparing the overuse index to structural indicators available in the Dartmouth 
Atlas. MethOds: A normalized JHOI was derived for 306 HRRs using a 5% sample 
of Medicare claims from 2008 and reflected overuse within each HRR. Inpatient 
and outpatient claims were used and claims from nursing homes were excluded. 
Potential drivers of overuse were derived from Dartmouth Atlas and regressed upon 
JHOI using ordinary least squares (OLS). Lagged covariates were used to prevent 
reverse causation. Huber-White standard errors were used to address clustering of 
HRR within states. Results: Exploratory analyses identified that the JHOI was posi-
tively associated with the number of acute-care beds (p< 0.001), medical specialists 
(p< 0.005), surgeons (p< 0.001), and the number of Medicare beneficiaries (p< 0.01) in 
an HRR. Regions with higher rates of appropriate testing of patients with diabetes 
(a proxy of process quality) (p< 0.05), more physicians (p< 0.001), and more nurses 
(p< 0.001) had less systematic overuse. cOnclusiOns: The use of cross-sectional 
data, collinearity between possible explanatory variables, and the relatively large 
unit of observation limit the interpretation of these findings as causal. This said, 
the intuitive nature of these findings suggests that there are likely structural driv-
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and model 1 + initiating-service groups (model 3). Optimism-corrected C-statistics 
and root mean square error (RMSE) were used to compare model prediction accu-
racy. Results: The cohort consisted of 3,105 individuals; of which 38.3% had a 
recurrent episode, with an average cost of $3,803CAD (SD= $11,959). LCA identified 
two groups: high user (15.2%) and low user (84.8%), while about 51.6% of the cohort 
was grouped as institutionalized. Model 2 predicted time to a subsequent episode 
better (C-statistic = 0.94) than model 3 (C-statistic = 0.91), and model 1 (C-statistic 
= 0.87). Model 3 predicted cost of the subsequent episode better (RMSE= 11934.5) 
than model 2 (RMSE= 11999.8) and model 1 (RMSE= 12075.3). cOnclusiOns: The 
findings suggest that both LCA-defined groups and initiating-service groups could 
be used to summarize past utilization for risk prediction modeling; the choice may 
depend on the outcome of interest.
PRM36
non-diScRetionaRy inPutS aRe iMPoRtant factoRS in hoSPital 
efficiency StudieS and Policy evaluation
Pasupathy K., Sir M.
Mayo Clinic, Rochester, MN, USA
Objectives: Hospital efficiency is the focus of several studies and increasingly, 
data envelopment analysis (DEA) is used to compute and compare efficiencies of 
hospitals for quality improvement and policy analysis. DEA is a non-parametric 
approach to compute efficiency considering multiple inputs and outputs and bench-
mark hospitals, with the presumption that the inefficient hospitals can reduce 
inputs and/or increase outputs to improve their efficiency. Hospitals are complex 
systems and have multiple non-discretionary inputs, such as type of hospital or 
region of location that are not under the control of administration, and hence cannot 
be altered. This study emphasizes the need to consider non-discretionary inputs 
in DEA models. MethOds: One year’s worth of Agency for Healthcare Research & 
Quality’s Health Care Utilization Project data was used. Variables included full-time 
equivalent of registered nurses, licensed practical nurses and nurse aides as inputs 
and total discharges and percent of surgeries as outputs, with bed size, urban/
rural, teaching status, region and ownership as non-discretionary inputs. First a 
variable-returns-to-scale DEA model was run without the non-discretionary inputs. 
Next the model was repeated including an environmental harshness (created using 
regression). Results: When the efficiency scores of the 862 hospitals in the two 
stages were compared, 755 hospitals had increased efficiency, and mean increased 
more than three times from 0.11 (P< 0.000) and standard deviation doubled from 
0.15. The number of efficient hospitals increased from 12 to 72. cOnclusiOns: 
DEA can be a sophisticated method to measure hospital efficiency. Not accounting 
for non-discretionary inputs can radically alter the efficiency scores and bias study 
results. The first stage score has inefficiency and the effect of non-discretionary 
inputs. Since both mean and standard deviation increased dramatically, simple nor-
malization cannot be used as a proxy. Appropriate treatment of non-discretionary 
inputs is necessary to make meaningful comparisons to inform quality and policy 
interventions.
PRM37
iMPact of Single RiSk factoR changeS on long-teRM outcoMeS and 
coSt in a tyPe 2 diabeteS Modeling Study contRaSting PRoJectionS 
with ukPdS68, SwediSh national diabeteS RegiStRy and the advance 
RiSk eQuationS
McEwan P.1, Lamotte M.2, Foos V.3
1Health Economics and Outcomes Research Ltd, Monmouth, UK, 2IMS Health Consulting, Brussels, 
Belgium, 3IMS Health, Basel, Switzerland
Objectives: Previous studies have investigated changes in risk factor (RF) variables 
on cost and outcomes in the IMS-CORE-Diabetes-Model (CDM) using UKPDS-68 
(UK-68-RE) and UKPDS-82 risk equations (UK-82-RE). The objective of this study 
was to project health benefits and total lifetime costs (TLC) associated with a range 
of selected RF changes utilizing UK-68-RE versus recently implemented RE within 
the CDM: the Swedish-National-Diabetes-Registry (S-NDR) and the ADVANCE-
Risk-Engine (ARE). MethOds: The CDM was applied to project the lifetime ben-
efits (life years (LYs), quality adjusted life years (QALYs)) and TLC ($US) associated 
with baseline RF changes for HbA1c (+/-1%), body-mass-index (BMI) (+/-1 Kg/m2), 
systolic-blood-pressure (SBP) (+/-20 mmHg), total-cholesterol (TC) (+/-10 mg/dl), 
(high-density-lipoprotein (HDL) (+/-5 mg/dl) and low-density-lipoprotein (LDL) (+/-
10 mg/dl). An intermediate risk type-2 diabetes cohort (age 52 years, HbA1c 8%, SBP 
140 mm-Hg, BMI 30 Kg/m2, HDL 50 mg/dl and LDL 150 mg/dl) was projected over 
lifetime to explore the sensitivity of discounted (3%) LYs, QALYs and TLC per unit RF 
variation. Results: When UK-68-RE were applied, projected changes in LYs were: 
0.096, 0.045, 0.013, 0.071, -0.183 and 0.0 and QALYS: 0.156, 0.067, 0.065, 0.051, -0.121 
and 0.0 for RF variations in HbA1c, SBP, BMI, TC, HDL and LDL, respectively. This 
compared to changes of 0.103, 0.032, 0.004, 0.070, -0.195, 0.044 (LYs) and 0.150, 0.049, 
0.054, 0.050, -0.132, 0.025 (QALYs) utilizing S-NDR-RE and 0.103, 0.030, 0.001, 0.065, 
-0.093, 0.0 (LYs) and 0.163, 0.057, 0.056, 0.048, -0.062, 0.0 (QALYs) utilizing ARE-RE. 
TLC decreased by $3’479, $1’065, $69, -$414, $1’263, $0, (UK-68-RE); $2’829, $852, $81, 
-$289, $910, -$347 (S-NDR-RE ) and $3’488, $1’196, -$10, -$182, $694, $0 (ARE-RE) for 
RF variations in HbA1c, SBP, BMI, TC, HDL and LDL, respectively. cOnclusiOns: 
The degree to which RF changes are translated into benefits and costs may change 
considerably dependent on the choice of selected risk equations.
PRM38
the coSt of dRug-Related MoRbidity that lead to eMeRgency viSitS 
in a bRazilian hoSPital
Freitas G.1, Balbinotto G.1, Hughes D.2, Heineck I.1
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Bangor University, Bangor, UK
Objectives: To investigate the costs associated with the management of patients 
who sought emergency care due to DRMs. MethOds: This study was a retrospec-
tive analysis of patients’ medical records. 535 patients sought emergency services 
over a six-month period in a large teaching hospital in Brazil and those with DRM 
situation 3; CIs cannot defined), the combination of the two proposed methods 
produces CIs as single range. cOnclusiOns: We reviewed the issues related to 
using the conventional methods to calculate ICER CIs, and proposed new methods 
to address these. Proposed methods yield CIs that can be more easily interpreted. 
However, some issues remain that require further discussion.
PRM33
Methodology uSing PhaRMacy and Medical claiMS data to evaluate 
Real-woRld outcoMeS and coStS of ivf tReatMent in the uS
Corvino F.A.1, Surinach A.1, Locklear J.C.2, Howe A.M.2, Hayward B.2, Mahony M.C.2
1Genesis Research, LLC, Hoboken, NJ, USA, 2EMD Serono, Inc., Rockland, MA, USA
Objectives: To describe the methodology used to identify treatment cycles and 
determine real-world outcomes associated with the in vitro fertilization (IVF) treat-
ments, follicle-stimulating hormone (FSH) versus FSH+human menopausal gonado-
tropin (hMG), using administrative claims data. MethOds: This retrospective study 
used the Truven Healthcare MarketScan® Claims Database to identify and compare 
IVF treatment protocols, pregnancy and birth outcomes among women aged 18–< 35 
undergoing IVF between January 2009 and December 2012. Patients with ≥ 1 claim for 
a gonadotropin-releasing hormone agonist (GnRHAg) or antagonist (GnRHAnt) (first 
claim being the index date), ≥ 1 claim for FSH and ≥ 1 claim for human chorionic gon-
adotropin (hCG), using National Drug Codes, were selected. Patients were included 
on identification of a prescription for FSH in the 7 days pre-index through 60 days 
post-index, hCG in the 60 days post-index and ≥ 1 embryo transfer (ET) code (using 
current procedural terminology) ≤ 60 days post-index. The FSH+hMG cohort also 
required identification of ≥ 1 claim for hMG ≤ 60 days post-index. Patient eligibility 
was defined as continuous enrollment for 12 months prior and 18 months post-
index. ICD-9-CM codes were used to identify live birth outcomes within 42 weeks 
of ET. Results: Inclusion/exclusion criteria identified 627 and 852 patients in the 
FSH and FSH+hMG cohorts, respectively. The 18-month post-index eligibility criteria 
accounted for a large number of patients removed (n= 7366). No differences in first-
cycle outcomes were seen between FSH and FSH+hMG for: live birth per ET (38.1% 
vs 38.5%; OR 1.02 [95%CI: 0.82–1.26], p= 0.871) and live birth per pregnancy (54.44% 
vs 54.37%; OR 1.00 [95%CI: 0.78–1.28], p= 0.98), respectively. cOnclusiOns: Most 
published analyses of fertility treatment outcomes are derived from single fertility 
center datasets. This methodology successfully identified two distinct IVF treatment 
protocols and allowed comparison of outcomes using real-world healthcare claims 
data sourced from a variety of fertility centers.
PRM34
a coSt analySiS of kidney theRaPy oPtionS
Younis M.1, Forgione D.2, Alkatib A.3, Jabr S.4, Hartmann M.5, Kisa A.6
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University of Jena, Jena, Germany, 6Zirve University, Gazyianteap, Turkey
Objectives: Kidney disease is a common condition in which kidneys fail to func-
tion properly. In this study, the highest incidence and prevalence rates of end-
stage renal disease [ESRD] (i.e.,both renal transplant and dialysis) were reported 
from the USA, Taiwan, and Japan. In the Arab countries of the Middle East, Saudi 
Arabia recorded the highest prevalence of patients with renal failure of 600 cases 
per million of population, while Kuwait recorded the lowest prevalence rate of 
80 cases per million. In the West Bank, the total number of renal failure patients 
was 692 in the first quarter of 2012—an increase of 11.3% over the same period in 
2011. MethOds: Prospective estimates and elicited expert opinions are used to esti-
mate the unit costs of hemodialysis and / or kidney transplantation in the Palestine. 
Our study retrospectively reviewed epidemiological data on hemodialysis including: 
1. Number of patients receiving hemodialysis; 2. Incidence rate; 3. Total mortality. 
The direct cost of kidney transplantation was estimated by dividing the procedures 
into three phases: (1) pre-transplant, (2) transplant, and (3) post-transplant. Cost 
analysis for hemodialysis was performed for each patient on dialysis. Results: 
The average cost for kidney transplant was US$16,277 for the first year; the esti-
mated cost of a single hemodialysis session was US$97; while the cost of hemo-
dialysis per patient was variable, it averaged $16,085 per year—nearly as much 
as a transplant. cOnclusiOns: While live, related kidney donors are scarce, our 
study revealed that kidney transplant was more adequate and less expensive than 
hemodialysis. These results were similar to many related studies, and have direct 
resource allocation implications for government-funded kidney disease services 
funded by through Palestinian Ministry of Health.
PRM35
aSSeSSing the incReMental PRedictive value of healthcaRe 
utilization PathwayS in RiSk PRediction Modeling
Kuwornu J.P.1, Lix L.1, Quail J.2, Wang E.2, Osman M.2, Teare G.2
1University of Manitoba, Winnipeg, MB, Canada, 2Saskatchewan Health Quality Council, 
Saskatoon, SK, Canada
Objectives: The study objective was to compare the incremental predictive value 
of a probability-based classification versus a deterministic grouping of previous 
healthcare use for subsequent healthcare outcomes. MethOds: Administrative 
databases from Saskatchewan, Canada (population 1.1 million) were used to identify 
an incident chronic obstructive pulmonary disease (COPD) cohort (35+ years). All 
episodes of healthcare use for COPD exacerbations between 2007/08 and 2011/2012 
fiscal years were identified. Latent class analysis (LCA) probabilistically grouped the 
cohort based on healthcare utilization in the index episode using visits to general 
practitioners (GP), specialists, emergency departments (ED), inpatient hospitaliza-
tions (IH), and outpatient medication dispensations. Individuals were also deter-
ministically grouped as institutionalized (IH/ED) or ambulatory (GP/specialist) based 
on the initiating service of the index episode. Time to a subsequent episode and 
the cost of the subsequent episode were modelled with Cox proportional hazard 
regression and generalized linear models, respectively; using only demographic 
and disease characteristics (model 1), model 1 + LCA-defined groups (model 2), 
